HK Stock Market Move | SKB BIO (06990) rose by over 5%, reaching the major endpoint of the global Phase III study of TROP2 ADC in collaboration with Merck.
Kolnbo Tao Biology (06990) rose more than 5%, as of the time of writing, it rose by 3.3% to 451.4 Hong Kong dollars, with a turnover of 166 million Hong Kong dollars.
SKB BIO (06990) rose by more than 5%, as of the time of writing, it has increased by 3.3%, trading at 451.4 Hong Kong dollars with a turnover of 166 million Hong Kong dollars.
On the news front, recently, according to SKB BIO's official announcement, Merck announced that the investigational TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) developed in collaboration with the company has achieved the main endpoints of overall survival (OS) and progression-free survival (PFS) in the pivotal Phase III TroFuse-005 trial for certain advanced or recurrent endometrial cancer patients.
TroFuse-005 is the first global Phase III trial targeting this patient population to demonstrate statistically significant improvements in overall survival (Os) and progression-free survival (PFS) compared to chemotherapy, and it is the first and only ADC drug to achieve this breakthrough in endometrial cancer patients.
Related Articles
HK Stock Market Move | Cathay Pacific Airways (00293) rose more than 3% with a 19% year-on-year increase in passenger volume in the first four months.
HK Stock Market Move | SUPER HI (09658) rose nearly 4%, with a 70.7% year-on-year increase in operating profit in the first quarter.
HK Stock Market Move | After the stock split, the stock prices of WELLCELL H-OLD (02940) and WELLCELL H-NEW (02477) experienced a sharp drop of over 80% in the morning session.
HK Stock Market Move | Cathay Pacific Airways (00293) rose more than 3% with a 19% year-on-year increase in passenger volume in the first four months.
HK Stock Market Move | SUPER HI (09658) rose nearly 4%, with a 70.7% year-on-year increase in operating profit in the first quarter.
HK Stock Market Move | After the stock split, the stock prices of WELLCELL H-OLD (02940) and WELLCELL H-NEW (02477) experienced a sharp drop of over 80% in the morning session.
